Daraxonrasib plus chemo for first-line metastatic pancreatic cancer
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a new targeted therapy (daraxonrasib) combined with standard chemotherapy as the first treatment for people whose pancreatic cancer has spread. The goal is to see if this combination can help shrink or control the cancer better than chemotherapy alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old and agree to take part in the study.
- You have been diagnosed with pancreatic cancer that has spread to other parts of the body within the last 6 weeks.
- Your cancer has a RAS mutation (or is the normal RAS type) as confirmed by a lab test.
- You are able to take pills by mouth.
- You have not had any prior chemotherapy or targeted therapy for metastatic pancreatic cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental daily pill, daraxonrasib, in people with pancreatic cancer that has been surgically removed. It’s for those who also had chemotherapy and have a specific DNA change called a RAS mutation. The goal is to see if the pill helps prevent the cancer from coming back.
This trial tests whether adding a new drug called zoldonrasib to standard chemotherapy works better than chemotherapy alone for pancreatic cancer that has spread and has a specific KRAS G12D mutation. The goal is to see if this combination helps patients live longer and control their cancer better.
This trial tests a new type of radiation called DaRT (Alpha DaRT) combined with standard chemotherapy for people with pancreatic cancer that is locally advanced or has spread. The goal is to see if adding this radiation treatment can help shrink tumors or slow the cancer's growth.
This program gives early access to an experimental pill called daraxonrasib for people whose pancreatic cancer has spread and has not responded to previous chemotherapy. It is not a regular clinical trial but a way to try the drug if no other options are available.
This trial tests a new combination treatment for pancreatic cancer that has spread or cannot be removed with surgery. The goal is to see if the combination can help control the cancer and is safe.
This trial tests a combination of chemotherapy (NALIRI-XELOX) plus a newer immunotherapy drug (AK104) as a first treatment for people with advanced pancreatic cancer that hasn't been treated yet. The goal is to see if this combination works better than standard treatments.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.